Cargando…

Gender Disparities in Prolactinomas: Unravelling Clinical Patterns, Metabolic Variations, and Treatment Responses

Background and objective Individuals with prolactinoma exhibit elevated rates of obesity, metabolic syndrome (MS), and dyslipidemia compared to their healthy counterparts. However, there is a lack of data regarding metabolic variance between male and female prolactinoma patients. Consequently, this...

Descripción completa

Detalles Bibliográficos
Autores principales: Baba, Mohammad Salem, Islam Mir, Sajad Ul, Bhat, Moomin Hussain, Laway, Bashir Ahmad, Misgar, Raiz Ahmad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10474902/
https://www.ncbi.nlm.nih.gov/pubmed/37664314
http://dx.doi.org/10.7759/cureus.42911
_version_ 1785100604942581760
author Baba, Mohammad Salem
Islam Mir, Sajad Ul
Bhat, Moomin Hussain
Laway, Bashir Ahmad
Misgar, Raiz Ahmad
author_facet Baba, Mohammad Salem
Islam Mir, Sajad Ul
Bhat, Moomin Hussain
Laway, Bashir Ahmad
Misgar, Raiz Ahmad
author_sort Baba, Mohammad Salem
collection PubMed
description Background and objective Individuals with prolactinoma exhibit elevated rates of obesity, metabolic syndrome (MS), and dyslipidemia compared to their healthy counterparts. However, there is a lack of data regarding metabolic variance between male and female prolactinoma patients. Consequently, this study aimed to investigate and compare sex-specific discrepancies in metabolic abnormalities among individuals diagnosed with prolactinoma. Methods In this prospective study, 80 treatment-naïve patients with prolactinoma (12 males and 68 females) underwent clinical assessments and laboratory investigations. The measured parameters included blood glucose, total cholesterol (TC), triglycerides (TG), LDL cholesterol (LDL-C), HDL cholesterol (HDL-C), urea, creatinine, uric acid, and blood glucose levels. The patients were treated with cabergoline, a dopamine agonist, and reevaluated after 12 weeks. Results Forty-eight patients had microprolactinomas (all females), and 32 had macroprolactinomas (20 females, 12 males). The mean age was 28.30±7.49 years for females and 28.91±7.12 years for males (p=0.71). The median symptom duration was 12 months (range 1-72 months, IQR 4-16 months), with no significant difference between males (median 12 months, IQR 5-54 months) and females (median 12 months, IQR 10-24 months, p=0.620). The median serum prolactin (PRL) was 988 ng/mL (IQR 471-1,439) in males and 165 ng/mL (IQR 90-425) in females (p<0.05). Males showed higher HbA1c, BGF, TC, TG, LDL-C, and higher rates of obesity, MS, and diabetes mellitus. Treatment with cabergoline resulted in significant improvements in the HbA1c, BGF, TC, TG, and LDL-C levels. Conclusion Males with prolactinomas had larger tumor sizes and higher serum PRL levels than females. Additionally, males exhibited worse metabolic parameters than females. However, there was no significant difference in the duration of symptoms or age at diagnosis between the two groups.
format Online
Article
Text
id pubmed-10474902
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-104749022023-09-03 Gender Disparities in Prolactinomas: Unravelling Clinical Patterns, Metabolic Variations, and Treatment Responses Baba, Mohammad Salem Islam Mir, Sajad Ul Bhat, Moomin Hussain Laway, Bashir Ahmad Misgar, Raiz Ahmad Cureus Endocrinology/Diabetes/Metabolism Background and objective Individuals with prolactinoma exhibit elevated rates of obesity, metabolic syndrome (MS), and dyslipidemia compared to their healthy counterparts. However, there is a lack of data regarding metabolic variance between male and female prolactinoma patients. Consequently, this study aimed to investigate and compare sex-specific discrepancies in metabolic abnormalities among individuals diagnosed with prolactinoma. Methods In this prospective study, 80 treatment-naïve patients with prolactinoma (12 males and 68 females) underwent clinical assessments and laboratory investigations. The measured parameters included blood glucose, total cholesterol (TC), triglycerides (TG), LDL cholesterol (LDL-C), HDL cholesterol (HDL-C), urea, creatinine, uric acid, and blood glucose levels. The patients were treated with cabergoline, a dopamine agonist, and reevaluated after 12 weeks. Results Forty-eight patients had microprolactinomas (all females), and 32 had macroprolactinomas (20 females, 12 males). The mean age was 28.30±7.49 years for females and 28.91±7.12 years for males (p=0.71). The median symptom duration was 12 months (range 1-72 months, IQR 4-16 months), with no significant difference between males (median 12 months, IQR 5-54 months) and females (median 12 months, IQR 10-24 months, p=0.620). The median serum prolactin (PRL) was 988 ng/mL (IQR 471-1,439) in males and 165 ng/mL (IQR 90-425) in females (p<0.05). Males showed higher HbA1c, BGF, TC, TG, LDL-C, and higher rates of obesity, MS, and diabetes mellitus. Treatment with cabergoline resulted in significant improvements in the HbA1c, BGF, TC, TG, and LDL-C levels. Conclusion Males with prolactinomas had larger tumor sizes and higher serum PRL levels than females. Additionally, males exhibited worse metabolic parameters than females. However, there was no significant difference in the duration of symptoms or age at diagnosis between the two groups. Cureus 2023-08-03 /pmc/articles/PMC10474902/ /pubmed/37664314 http://dx.doi.org/10.7759/cureus.42911 Text en Copyright © 2023, Baba et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Endocrinology/Diabetes/Metabolism
Baba, Mohammad Salem
Islam Mir, Sajad Ul
Bhat, Moomin Hussain
Laway, Bashir Ahmad
Misgar, Raiz Ahmad
Gender Disparities in Prolactinomas: Unravelling Clinical Patterns, Metabolic Variations, and Treatment Responses
title Gender Disparities in Prolactinomas: Unravelling Clinical Patterns, Metabolic Variations, and Treatment Responses
title_full Gender Disparities in Prolactinomas: Unravelling Clinical Patterns, Metabolic Variations, and Treatment Responses
title_fullStr Gender Disparities in Prolactinomas: Unravelling Clinical Patterns, Metabolic Variations, and Treatment Responses
title_full_unstemmed Gender Disparities in Prolactinomas: Unravelling Clinical Patterns, Metabolic Variations, and Treatment Responses
title_short Gender Disparities in Prolactinomas: Unravelling Clinical Patterns, Metabolic Variations, and Treatment Responses
title_sort gender disparities in prolactinomas: unravelling clinical patterns, metabolic variations, and treatment responses
topic Endocrinology/Diabetes/Metabolism
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10474902/
https://www.ncbi.nlm.nih.gov/pubmed/37664314
http://dx.doi.org/10.7759/cureus.42911
work_keys_str_mv AT babamohammadsalem genderdisparitiesinprolactinomasunravellingclinicalpatternsmetabolicvariationsandtreatmentresponses
AT islammirsajadul genderdisparitiesinprolactinomasunravellingclinicalpatternsmetabolicvariationsandtreatmentresponses
AT bhatmoominhussain genderdisparitiesinprolactinomasunravellingclinicalpatternsmetabolicvariationsandtreatmentresponses
AT lawaybashirahmad genderdisparitiesinprolactinomasunravellingclinicalpatternsmetabolicvariationsandtreatmentresponses
AT misgarraizahmad genderdisparitiesinprolactinomasunravellingclinicalpatternsmetabolicvariationsandtreatmentresponses